Phase 26 · Coverage readiness
Build-in-public roadmap
Some metrics use fallback, fixture or mixed sources and are marked unverified-source rather than met or below-target.
Exact progress toward the roadmap’s first-year lower bounds. Missing work stays visible; counts are never presented as scientific quality or approval.
Source composition
- Graph data source: live
- Product data source: checked-in-fixture
- Graph latest evidence: 2026-07-19T03:26:07.623Z
- Products latest observation: 2026-07-22T06:45:00.000Z
- Data-bound asOf: 2026-07-22T06:45:00.000Z
- Source snapshot: sha256:c160872826def812cd0d20c00ff38c80cf67612312c62a1464603f2003c5758c
- Receipt: available for independent verification
| Target | Observed | Minimum | Gap | Status | Assessment |
|---|---|---|---|---|---|
| Deeply covered canonical ingredients Canonical graph.interventions with entityKind ingredient and at least three distinct eligible outcome families from accountably reviewed claims, resolvable provenance on each counted claim, and a published safety edge with resolvable provenance (an ingredient×drug interaction or a contraindication). Combination or unknown entity kinds never count even when admitted to supplements-baseline. | 0 | 100 | 100 | below target | conservative proxy |
| Goals or conditions (outcome proxy) Distinct outcome IDs attached to at least one currently publishable claim. This is an outcome-based proxy, not a direct count of canonical goal or condition entities. | 19 | 30 | 11 | below target | conservative proxy |
| Published accountably human-reviewed claims Currently publishable, source-grounded claims with explicit human review, strict claim-scoped governance, persisted governed reviewer approval records for methodology and clinical-safety, and explicit safety review evidence; aggregate quorum flags or recomputed hashes alone do not count. | 0 | 1,000 | 1,000 | below target | direct count |
| Structured studies represented Union of eligible structured study identities and eligible resolvable cited-work identities from the accountably reviewed claim set; malformed, fixture-only, or unresolvable identities are excluded and duplicate study families count once. | 0 | 5,000 | 5,000 | below target | conservative proxy |
| Products mapped to evidence Reviewed-stable commercial product identities with distinct product, formulation, and label IDs, a persisted admitted ProductEvidenceLink matching exact product/formulation and accountably reviewed claim revision, provenance-bearing label records, and matching intervention linkage; self-asserted commercialIdentity.evidence linkage strings and source-scoped products are excluded and this is not quality verification or recommendation. | 0 | 5,000 | 5,000 | unverified source | direct count |
External operations
- Professional pilot: not externally verified.
- Laboratory program: not externally verified.
- External adoption: not claimed.
- Public-data license: pending governance ratification.
Inventory, proxy coverage and software capability do not establish scientific completeness, clinical approval, product quality, laboratory testing, professional adoption, regulatory acceptance or external use.